This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Not applicable	<i>In vitro</i> and mouse studies suggest that cholesterol sequestering could improve the efficacy of endostatin for cancer treatment. In endothelial cells, the cholesterol-sequestering agent nystatin increased the internalization of the generic antiangiogenic compound endostatin. In tumor-bearing mice, nystatin increased the uptake of endostatin by tumor blood vessels and decreased tumor volume and weight compared with saline. Next steps include determining the optimized treatment regimen using endostatin and nystatin.	Findings patented by Tsinghua University and Protgen Ltd.; available for licensing	Chen, Y. <i>et al. Blood</i> ; published online April 11, 2011; doi:10.1182/blood-2010-12-322867 Contact: Yongzhang Luo, Tsinghua University, Beijing, China e-mail: yluo@tsinghua.edu.cn
<i>SciBX</i> 4(17); doi:10.1038/scibx.2011.480 Published online April 28, 2011				